The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a significant substantial loss in body mass and improve metabolic health, par